Health System

Five facets of the OxyContin dilemma

A longtime RPh ponders the midlife cost of her new PharmD degree.

A look at what's going on with the Continuing Professional Development initiative from ACPE.

A survey of new Rx, new generic, and new OTC products

A round-up of OTC products that provide fresh breath and help promote good oral health.

We can learn from New Zealand, Japan, and Pakistan

In 2012, FDA achieved a milestone with the approval of 39 innovative drug therapies for populations in need.

After years of declining pipeline productivity, are we headed for a resurgence in new approvals? Here's a look at what's ahead for 2013.

Intravenous abuse of Opana ER may be at risk of thrombotic thrombocytopenic purpura according to a report published in MMWR.

According to the numbers, at-home test kits are going to continue to be an area of market growth.

A new bimonthly column from Ken Baker looks at ethical decision-making in pharmacy.

A universal antidote for factor Xa inhibitors has entered phase 2 studies.

NSAIDs plus ACE inhibitors or ARBs can increase risk of kidney injury for patients taking diuretics.

Recent data were released on a long-term, open-label extension study evaluating clobazam for the adjunctive treatment of drop seizures.

Auto-programming infusion pumps reduces keystroke error and increases patient safety.

Pharmacy techs speak out.

Are pharmacists losing the love?

CMS recently approved 106 new ACOs in Medicare, including three of Walgreens' health networks.